This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huang, K.-C. Articles by Ng, S.-W. Search for Related Content PubMed PubMed Citation Articles by Huang, K.-C. Articles by Ng, S.-W.

Laboratory of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115 [K-C. H., S. C. M., R. S. B., S-W. N.]; Baylor College of Medicine, Texas Children’s Cancer Center, Houston, Texas 77030 [P. H. R., C. C. L.]; CNRS, Institut Curie-Recherche, 75248 Paris, France [E. H.]; Centre of Statistics, Department of Mathematics, University of Queensland, St. Lucia, Brisbane, QLD 4072, Australia [S-K. N.]; and Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, V6T 1Z3, Canada [C. B.]

Expression profiling to characterize cancer pharmacology has become a new approach to discover novel molecular targets for prognostic markers and cancer therapy. In a study to compare the global RNA expression profiles between primary and recurrent ovarian tumors from the same patient, we have identified XIST (inactive X chromosome-specific transcripts) as the most differentially expressed gene that was down-regulated in the recurrent tumor. XIST encodes a spliced noncoding polyadenylated transcript that is unique in being expressed exclusively from the inactive X chromosome and is involved in the X-inactivation process. Subsequent characterization of XIST expression in a panel of female cancer cell lines showed that the expression level of XIST correlates significantly with Taxol sensitivity. The clinical relevance of this observation is demonstrated by the strong association between XIST RNA levels and disease-free periods of ovarian cancer patients in a group of 21 ovarian cancer cases with Taxol in the therapeutic regiments. Cytogenetic studies on ovarian cancer cell lines indicated that loss of inactive X chromosome is one mechanism for the loss of XIST transcripts in the cell lines. Our data suggest that XIST expression may be a potential marker for chemotherapeutic responses in ovarian cancer.

This article has been cited by other articles:

				F. Savarese, K. Flahndorfer, R. Jaenisch, M. Busslinger, and A. Wutz Hematopoietic precursor cells transiently reestablish permissiveness for x inactivation. Mol. Cell. Biol., October 1, 2006; 26(19): 7167 - 7177. [Abstract] [Full Text] [PDF]

				L. R. Vasques, R. Stabellini, F. Xue, X. C. Tian, M. Soukoyan, and L. V. Pereira XIST Repression in the Absence of DNMT1 and DNMT3B DNA Res, January 1, 2005; 12(5): 373 - 378. [Abstract] [Full Text] [PDF]